-A new study has demonstrated the enhanced ability of an optimized 20-nucleotide derivative of a larger DNA aptamer to bind myelin in a mouse model of Multiple Sclerosis. The study, which also provides the first evidence of cross-reactivity of this myelin-binding aptamer with human brain cells, is published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text of this open access article on the Nucleic Acid Therapeutics website.
The laboratories of L. James Maher, III and Moses Rodriguez from Mayo Clinic College of Medicine and Science (Rochester, MN) coauthored the article entitled "Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy." The researchers took a 20-nucleotide region of a parental 40-nucleotide myelin-binding DNA aptamer and used a rational, non-biased approach to molecular evolution to optimize the 20-nucleotide minimal sequence for improved myelin binding. They conclude that due to its cross-reactivity with human oligodendroglioma cells in vitro, it represents a promising lead molecule for further investigation.
"The authors highlight the value of aptamer refinement of a therapeutic for Multiple Sclerosis treatment and present a novel application for cell imaging," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
Research reported in this publication was supported by the National Institutes of Health under Award Numbers T32GM065841 and F30CA220660.
Journal Reference:Brandon Wilbanks, John Smestad, Robin M. Heider, Arthur E. Warrington, Moses Rodriguez, L. James Maher. Optimization of a 40-mer Antimyelin DNA Aptamer Identifies a 20-mer with Enhanced Properties for Potential Multiple Sclerosis Therapy. Nucleic Acid Therapeutics, 2019; DOI: 10.1089/nat.2018.0776
Cite This Page:
Mary Ann Liebert, Inc./Genetic Engineering News. "Researchers optimize aptamer with enhanced myelin-binding properties for MS treatment." ScienceDaily. ScienceDaily, 27 March 2019. <www.sciencedaily.com/releases/2019/03/190327112702.htm>.
Mary Ann Liebert, Inc./Genetic Engineering News. (2019, March 27). Researchers optimize aptamer with enhanced myelin-binding properties for MS treatment. ScienceDaily. Retrieved June 15, 2019 from www.sciencedaily.com/releases/2019/03/190327112702.htm
Mary Ann Liebert, Inc./Genetic Engineering News. "Researchers optimize aptamer with enhanced myelin-binding properties for MS treatment." ScienceDaily. www.sciencedaily.com/releases/2019/03/190327112702.htm (accessed June 15, 2019).
Jan. 4, 2018 — Multiple Sclerosis is a chronic inflammatory disease of the central nervous system, in which the immune cells attack myelin sheaths. Regeneration of myelin sheaths is necessary for patients to ... read more
Dec. 1, 2016 — Multiple Sclerosis is an autoimmune disease in which the body's immune system attacks the patient's own cells. In this case, modified T cells destroy the myelin sheath surrounding nerve ... read more
July 31, 2015 — A technique to analyze various target DNAs has been developed using an aptamer, a DNA fragment that can recognize and bind to a specific protein or ... read more
Feb. 27, 2015 — A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of Multiple Sclerosis, according to a study. Multiple Sclerosis is a ... read more